There is no standard treatment for giant-cell tumour of bone (GCTB), a rare but very aggressive osteolytic tumour. In a phase II open-label trial in adults or adolescents with histologically confirmed GCBT, 282 patients were divided into three cohorts based on whether tumours were surgically salvageable or based on prior treatment with denosumab. Denosumab reduced the need for morbid surgery, representing a new therapy option for these patients with GCTB.
References
Chawla, S. et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel group, phase 2 study. Lancet Oncol. 10.1016/S1470-2045(13)70277-8
Rights and permissions
About this article
Cite this article
Denosumab—new treatment option for GCTB. Nat Rev Clin Oncol 10, 487 (2013). https://doi.org/10.1038/nrclinonc.2013.140
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2013.140